Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide roll-over study in participants from prior Bayer darolutamide trials
jRCT2031200304Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Open-label, single-arm trial of darolutamide in cancer, sponsored by Bayer. Primary endpoint: Safety. Started Dec 2020; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2031200304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200304.